Symrise AG (SYIEY) Stock Price & How to Invest

Symrise AG develops and makes flavors, fragrances and functional ingredients that other companies put into their own products: the taste in a soft drink or snack, the scent in a shampoo or fine perfume, the palatability coating that makes dry pet food appealing to cats and dogs, and active ingredients such as UV filters and preservatives for cosmetics. It sells to food, beverage, pet-food, personal-care and household-goods manufacturers worldwide and earns money on volume of ingredients sold, usually under long-running supply relationships where a flavor or scent is written into a customer's formula. In 2025 Symrise reported sales of ~€4.93 billion, up 2.8% organically, with foreign exchange and portfolio changes taking about €210 million off the reported figure.

The business runs in two segments. Taste, Nutrition & Health (TN&H) brought in ~€3.03 billion in 2025, about 61% of group sales, at a 23.8% adjusted EBITDA margin. It includes Food & Beverage (flavors, with beverages growing high single digits in 2025), Pet Food (palatability enhancers and pet-food ingredients, built largely on the 2014 purchase of France's Diana group) and probiotics through Probi. Scent & Care (S&C) brought in ~€1.90 billion at an 18.9% margin and covers Fragrance (fine fragrance plus consumer fragrance for detergents and toiletries), Cosmetic Ingredients and Aroma Molecules such as menthol and other synthetic aroma chemicals. In its H1 2026 report Symrise pointed to recovering momentum in North America and Asia Pacific.

The company traces its roots to two firms in Holzminden, Lower Saxony, where it is still headquartered. Haarmann & Reimer was founded in 1874 to make synthetic vanillin, and Dragoco was founded in 1919. The private-equity firm EQT combined them in 2003 to form Symrise, which listed on the Frankfurt Stock Exchange in December 2006 and moved into the DAX blue-chip index when it expanded to 40 members in 2021. Dr. Jean-Yves Parisot, who joined Symrise in 2014, became CEO on 1 April 2024, succeeding Dr. Heinz-Jürgen Bertram after his roughly 15 years in the role; Parisot's contract now runs to September 2028. The shares are widely held by institutions, and Symrise has no controlling shareholder.

For investors the picture is a defensive compounder that has been growing more slowly than it promised. Adjusted EBITDA margin rose 120 basis points to 21.9% in 2025, adjusted business free cash flow hit a record ~€780 million, and leverage fell to 1.9 times. Reported earnings were held down by ~€298 million of impairments on the terpene business and the Swedencare stake, which is why IFRS EPS was €1.78 against adjusted EPS of €3.67. In 2026 the company launched its first share buyback (up to €400 million, running to 30 October 2026) and raised the dividend for a sixteenth year. H1 2026 sales were ~€2.54 billion with organic growth of 2.0%, accelerating to 4.5% in the second quarter. SYIEY itself is an unsponsored ADR issued by Citibank, and per Citibank's 2013 ratio notice four ADRs represent one Frankfurt-listed share.

The largest risk is growth falling short of plan. Organic growth of 2.8% in 2025 and 2.0% in H1 2026 sits well under the 5% to 7% medium-term target, and the stock's ~25 times multiple of 2025 adjusted EPS (€92.24 share price in October 2026 against €3.67) assumes the business returns to something closer to its historic pace. Pet Food is in price normalization after earlier increases, so revenue there can fall even when volumes hold. Raw materials are a second risk: Symrise buys citrus, vanilla, mint and other naturals plus petrochemical feedstocks, and sudden cost spikes can squeeze margins before price increases catch up. The H1 2026 report already cited higher logistics costs tied to the Middle East. Currency is a third: reported sales lost about €210 million in 2025 to FX and portfolio effects, and an investor holding SYIEY in dollars carries euro exposure on top of the company's own mix of dollar, emerging-market and euro revenue. Past acquisitions have produced write-downs, including ~€150 million on Swedencare and ~€148 million on terpenes in Q4 2025, so further M&A such as Floral Concept carries integration and valuation risk. The ONE SYM transformation spends money now for savings later, and it may take longer than planned. Competition from Givaudan, dsm-firmenich and IFF is intense, and large consumer-goods customers have significant purchasing power. Finally, SYIEY is an unsponsored ADR traded over the counter, so volume is thin, spreads can be wide, Citibank may deduct depositary fees from dividends, and German withholding tax of 26.375% applies before any treaty reclaim.

We give no verdict on Symrise AG. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Organic growth recovering from a weak first quarter. Symrise guided for Q1 2026 organic sales to fall by a low single-digit percentage, and they did, before organic growth recovered to 4.5% in Q2.

The case against. The largest risk is growth falling short of plan.

Read the full bull and bear case on SYIEY, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Symrise AG's investor relations page or your broker.

• Revenue (FY2025): ~€4.93B (+2.8% organic)
• Revenue (H1 2026): ~€2.54B (+2.0% organic)
• Adjusted EBITDA margin (H1 2026): ~21.8%
• Adjusted EPS (FY2025): €3.67 (IFRS €1.78)
• Net debt / adjusted EBITDA: ~2.2x (June 2026)
• Dividend (FY2025): €1.25 per share

At the €92.24 Frankfurt share price shown on Symrise's investor page in October 2026, the stock trades at roughly 25 times 2025 adjusted EPS. That is a premium multiple for a company growing low single digits, and it reflects the predictability of flavor and fragrance demand plus margins near 22%. The gap between adjusted EPS (€3.67) and IFRS EPS (€1.78) comes mostly from the Q4 2025 impairments on terpenes and Swedencare, which were non-cash. The €1.25 dividend equals a yield of about 1.4% at that price, before German withholding. Because four SYIEY ADRs equal one share, each ADR represents about a quarter of the per-share figures above, converted to dollars.

Other names that sit close to SYIEY: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get SYIEY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SYIEY sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where SYIEY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Symrise is a mature, cash-generative ingredients supplier with sixteen straight dividend increases, priced at roughly 25 times adjusted earnings. The open question for SYIEY holders is whether organic growth climbs from the 2% to 4% guided for 2026 toward the 5% to 7% the company targets through 2028.

Whether SYIEY is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SYIEY a buy or a sell?, and where the stock could go from here in the SYIEY stock forecast.

For income investors, whether SYIEY pays a dividend and how the payout looks is covered in does SYIEY pay a dividend? And to weigh SYIEY against a peer, read the full side-by-side comparisons: SYIEY vs IFF and SYIEY vs ADM.